88965-00-8

Basic information

• Product Name: 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine
• Synonyms: 6-METHYL-2-P-TOLYL-IMIDAZO[1,2-A]PYRIDINE;6-methyl-2-(4-methylphenyl)imidazo[1,2-alpha]pyridine;6-Methyl-2-(4-methylphenyl-imidazo[1,2-a]pyridine;ZolpidemTartrate1.6-Methyl-2-(4-Methylphenyl)Imidazo[1,2-A]Pyridine;IMIDAZO[1,2-A]PYRIDINE, 6-METHYL-2-(4-METHYLPHENYL)-;6-METHYL-2-P-TOLY-IIDAZOLE(1,2)PYRIDINE;6-methyl-2-p-tolylimidazo[1,2-a]pyridin
• CAS NO: 88965-00-8
• Molecular Formula: C₁₅H₁₄N₂
• Molecular Weight: 222.29
• Product Categories: Pyridines derivates
• Mol File: 88965-00-8.mol
• Article Data: 30

Chemical Properties

• Appearance: /
• Density: 1.09g/cm3
• Refractive Index: 1.615
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 7.07±0.50(Predicted)
• CAS DataBase Reference: 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine(88965-00-8)
• EPA Substance Registry System: 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine(88965-00-8)

Safety Data

• Hazardous Substances Data: 88965-00-8(Hazardous Substances Data)

Usage

Uses

6-Methyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine is an impurity of Zolpidem (Z650000), a selective non-benzodiazepine GABAA receptor agonist.

InChI:InChI=1/C15H14N2/c1-11-3-6-13(7-4-11)14-10-17-9-12(2)5-8-15(17)16-14/h3-10H,1-2H3

Upstream product

• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 619-41-0 4-(bromoacetyl)toluene 
• 4209-24-9 p-methylphenacyl chloride 
• 766-97-2 4-n-methylphenylacetylene 
• 122-00-9 para-methylacetophenone 
• 1003-68-5 5-methyl-2-pyridone 

Downstream Products

• 118026-14-5 N,N,6-trimethyl-2-(4-methylphenyl)-imidazo[1,2-α]pyridine-3-α-hydroxyacetamide 
• 106961-33-5 dimethyl-(6-methyl-2-p-tolylimidazo[1,2-a]pyridin-3-ylmethyl)-amine 
• 959605-49-3 d14-6-methyl-2-p-tolyl-imidazo[1,2-a]pyridine 
• 768398-03-4 6-methyl-3-cyanomethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine 
• 189005-44-5 6-methyl-2-(4-methylphenyl)-imidazo<1,2-a>pyridine-3-acetic acid 
• 365213-58-7 2-(4-methylphenyl)-6-methylimidazo[1,2-α]pyridine-3-acetamide 
• 82626-48-0 N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide 
• 106961-34-6 Trimethyl-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-ammonium; iodide 
• 400777-11-9 6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridine-3-carbaldehyde 
• 1609583-50-7 6-methyl-3-(phenylthio)-2-(p-tolyl)imidazo[1,2-a]pyridine 
• 193979-47-4 ethyl 6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetate 

Relevant articles and documents

Synthetic method of imidazopyridine compounds

The invention provides a novel method for synthesizing imidazopyridine compounds. According to the invention, aminopyridine compounds and sulfur ylide are used as original reaction substrates, iron phthalocyanine (FeIIPc) is used as a catalyst, and a series of the imidazopyridine compounds are obtained under the condition that the advantages of mildness, greenness, high efficiency, wide substrateuniversality and the like are achieved.

Design, synthesis and anticancer activity of sulfenylated imidazo-fused heterocycles

We report herein, the design, synthesis and study of anticancer properties of sulfenylated 2-phenylimidazo[1,2-a]pyridines and their analogues. A set of twenty sulfenylated imidazo[1, 2-a]pyridine derivatives were synthesized. Whereby elusive amendments to the imidazo[1,2-a]pyridine motif confer dramatic changes in functional affinity of a novel action to modulate anticancer activity in seven different human cancer cell lines i.e.: MDA MB 231 (breast), HepG2 (liver), Hela (cervical), A549 (lung), U87MG (glioblastoma), SKMEL-28 (skin melanoma) and DU-145 (prostate) by employing MTT assay. Among the series, compounds 4e (naphthalene), 4f (styrene) and 4h (thiomethyl) showed potent activity towards human liver cancer cells HepG2. Cell cycle analysis results revealed that these compounds arrested the cell cycle at G2/M phase and induced apoptosis in human liver cancer cells HepG2. It was further confirmed by Hoechst staining, Measurement of mitochondrial membrane potential (ΔΨm) and Annexin V-FITC assay.

Design, one-pot green synthesis and antimicrobial evaluation of novel imidazopyridine bearing pyran bis-heterocycles

Herein, we report design, one pot synthesis and antibacterial evaluation of novel imidazopyridine bearing pyran bis-heterocycles. The compounds were synthesized in an aqueous solution of gluconic acid under both conventional heating and ultrasound irradiation. The target compounds were obtained in good to moderate yields with yield of 65–88% in 20–60 min under ultrasonic irradiation. The compounds were characterized by spectroscopic methods IR, 1H NMR, 13C NMR, MS and HRMS. X-ray single crystal structure of 7i was also determined. The compounds were evaluated for antibacterial activity by measuring zone of inhibition using disk diffusion method that revealed that some compounds were inhibiting the growth of Gram +ve and Gram -ve bacteria. Result of minimum inhibitory concentration (MIC) showed that 7a, 7h & 7k from a series 7a-7k inhibited the growth of S. aureus. The minimum bactericidal concentration (MBC) value was determined for 7a, 7h & 7k. MBC/MIC ratio of the derivatives 7a, 7k & 7h suggest former two derivatives act as bactericidal agent & later act as bacteriostatic agents against Gram +ve bacteria. Haemolysis results showed that compounds are non-cytotoxic to erythrocytes.